Transcatheter Aortic Valve Replacement Market to Hit USD 13.58 Billion by 2035; U.S. to Reach USD 4.20 Billion as Minimally Invasive Cardiac Care Expands | SNS Insider

Europe is projected to reach USD 3.83 billion by 2035, while rising adoption of minimally invasive valve procedures, an aging population, and advances in transcatheter valve technology drive global TAVR market growth.

Austin, United States, Aug. 14, 2026 (GLOBE NEWSWIRE) — According to SNS Insider, The Transcatheter Aortic Valve Replacement Market was valued at USD 6.78 billion in 2025 and is projected to reach USD 13.58 billion by 2035, registering a CAGR of 7.21% during 2026-2035. Growth is being supported by the rising adoption of minimally invasive cardiac procedures, increasing prevalence of aortic stenosis, an aging population, and continued advances in transcatheter valve technologies.

Download the Transcatheter Aortic Valve Replacement Market Sample Report: https://www.snsinsider.com/sample-request/10458

Key Takeaways:

• Leading Application: Aortic Stenosis (~82.40% share)
• Leading Procedure Type: Transfemoral (~88.58% share)
• Leading End User: Hospitals (~76.50% share)
• Leading Valve Type: Balloon-Expandable (~54.60% share)
• Largest Regional Market: North America (~39.20% share)
• Fastest-Growing Regional Market: Asia Pacific

Rising Valve Technology Innovation Underpins Steady Growth Globally

Improvements in technologies for balloon expandable as well as self-expandable valves have improved the procedure’s success rate and the outcomes for the patient, whereas advancements in imaging guidance technology have further reduced the complications involved during the process. Transfemoral techniques of access have made the procedure minimally invasive and less complicated, and there is evidence from a randomized trial that low-risk patients experience a 15.5% composite rate of death or disabling stroke in five years compared to 16.4% with surgery.

Regional Insights:

North America held the largest market share of around 39.20% in 2025 due to advanced infrastructure facilities for cardiology treatment and higher adoption rate of the procedure in the U.S. and Canada. Higher adoption rate of transfemoral procedures and self-expandable valves, along with research activities and aging population, is making North America the leading region in the field of TAVR.

The U.S. Transcatheter Aortic Valve Replacement Market size in 2025 is estimated at USD 2.30 billion and is expected to reach around USD 4.20 billion by 2035, growing at a CAGR of 6.25% during the forecast period from 2026 to 2035. The U.S. continues to dominate the market on account of high prevalence of aortic stenosis, increased preference for minimally invasive cardiac surgeries, and skilled cardiac surgeons.

The Europe Transcatheter Aortic Valve Replacement Market size is expected to reach USD 1.97 billion in 2025 and to grow to USD 3.83 billion by 2035, registering a CAGR of approximately 6.90% during 2026-2035, accounting for approximately 29.0% of total global market share. Europe has been marked by a robust growth rate that has been fueled by favorable reimbursement policies and increasing structural heart programs in Germany, France, the United Kingdom, and Italy along with the growing use of minimally invasive valve implantation.

Asia Pacific is expected to record the fastest CAGR during the forecast period, propelled by the quick expansion of cardiac care infrastructure as well as the increasing prevalence of cardiovascular diseases in countries, such as China, Japan, India, and South Korea. The increasing hospital network, growing awareness regarding minimally invasive therapies, and rising affordability of advanced valve systems are continuing to drive regional market growth.

Segmentation Analysis

By Application: The Aortic Stenosis market held a share of approximately 82.40% in 2025 due to factors such as high prevalence rate among the geriatric population, enhanced screening process, well-defined treatment guidelines, and favorable reimbursement scenario. The Aortic Regurgitation market was growing at a CAGR of 14.21% during the forecast period, owing to increased use of transcatheter procedures to treat difficult valve cases.

By Procedure Type: The segment of transfemoral held major market share at 88.58%, due to its less invasive technique, success rate of procedure, quick recovery, and shorter stay in hospitals. The fastest growing segment is that of transapical, with a CAGR of 13.88%. It can be attributed to the expanding applicability of this procedure in people who cannot undergo transfemoral approach, and those with complex anatomies.

By End User: In 2025, Hospitals accounted for a major market share of 76.50% due to the presence of sophisticated catheterization laboratories, skilled cardiac surgeons, and ability to perform complicated TAVR procedures. Ambulatory surgical centers have become the most rapidly developing end users in the market with a growth rate of 15.40% CAGR due to preference for minimally invasive cardiac surgeries.

By Valve Type: Balloon-Expandable was the largest market player, accounting for approximately 54.60% in 2025, due to its procedural precision, good clinical results, minimal paravalvular leakage, and ample experience among physicians of reimbursement opportunities. Self-Expanding is the most rapidly growing valve, with a CAGR of 9.84% during the forecast period, due to increased demand for repositionable valves.

Explore the Complete Transcatheter Aortic Valve Replacement Market Report: https://www.snsinsider.com/reports/transcatheter-aortic-valve-replacement-market-10458

Leading Market Players Listed in this Report are:

• Edwards Lifesciences
• Medtronic
• Abbott Laboratories
• Boston Scientific Corporation
• JenaValve Technology
• JC Medical Inc.
• Venus Medtech (Hangzhou) Inc.
• MicroPort Scientific Corporation
• Lepu Medical Technology
• Meril Life Sciences Pvt. Ltd.
• Peijia Medical Limited
• Braile Biomédica
• Colibri Heart Valve LLC
• Artivion Inc.
• LivaNova PLC
• Shandong Weigao Group Medical Polymer Co., Ltd.
• Blue Sail Medical Co., Ltd.
• Medinol Ltd.
• Terumo Corporation
• Hangzhou NuMED Medical Co., Ltd

Recent Developments:

• 2026: Medtronic gained FDA approval for Mosaic Neo bioprosthetic mitral valve and initiated U.S. commercial rollout with early robotic implantation use.
• 2025: Edwards Lifesciences received FDA approval for Sapien M3 transcatheter mitral valve replacement system, expanding its structural heart therapy portfolio.

Frequently Asked Questions (FAQs):

Q: What is the expected CAGR of the transcatheter aortic valve replacement market from 2026 to 2035?
A: The market is expected to grow at a CAGR of 7.21% from 2026 to 2035.

Q: What was the size of the transcatheter aortic valve replacement market in 2025?
A: The market was valued at USD 6.78 billion in 2025.

Q: What is the major growth factor driving the transcatheter aortic valve replacement market?
A: Rising preference for minimally invasive cardiac procedures and technological advancements in valve design are the major growth drivers.

Q: Which application segment dominated the transcatheter aortic valve replacement market?
A: Aortic Stenosis dominated with around 82.40% share in 2025.

Q: Which region dominated the transcatheter aortic valve replacement market in 2025?
A: North America dominated with around 39.20% share in 2025.

Buy the Transcatheter Aortic Valve Replacement Market Report with Competitive Analysis and 2035 Forecast: https://www.snsinsider.com/checkout/10458

Transcatheter Aortic Valve Replacement Market Report Scope

Report Attributes	Details
Market Size in 2025	USD 6.78 Billion
Market Size by 2035	USD 13.58 Billion
CAGR	CAGR of 7.21% From 2026 to 2035
Base Year	2025
Forecast Period	2026-2035
Historical Data	2022-2024
Key Segments	• By Application (Aortic Stenosis, Aortic Regurgitation, Congenital Heart Defects, Heart Failure) • By Procedure Type (Transfemoral, Transapical, Subclavian, Direct Aortic) • By End User (Hospitals, Ambulatory Surgical Centers, Cardiology Clinics) • By Valve Type (Balloon-Expandable, Self-Expanding, Surgical Aortic Valve Replacement)
Regional Analysis/Coverage	North America (US, Canada), Europe (Germany, UK, France, Italy, Spain, Russia, Poland, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Australia, ASEAN Countries, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Mexico, Colombia, Rest of Latin America).

Recently Published Press Releases

Vaccine Adjuvants Market Size To Exceed $6.19 Billion By 2035

Ophthalmic Clinical Trials Market Size To Exceed $3.30 Billion By 2035

Specialty Generics Market Size To Exceed $295.53 Billion By 2035

Human Growth Hormone Market Size To Exceed $26.14 Billion By 2035

About Us:

SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company’s aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

CONTACT: Rohan Jadhav - Principal Consultant
Phone: +1-315-961-9094 (US)
Email: info@snsinsider.com

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. TheNewsHeadliner.com takes no editorial responsibility for the same.